Navigation Links
Encision Reports Profitable Third Fiscal Quarter Results
Date:1/28/2010

BOULDER, Colo., Jan. 28 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its third quarter of fiscal year 2010.

Net sales for the three months ended December 31, 2009 and December 31, 2008 totaled $3.3 million. The Company recorded net income of $149 thousand, or $.02 per share, for the third quarter of fiscal year 2010, compared to a net income of $233 thousand, or $.04 per share, for the third quarter of fiscal year 2009. Gross profit margin for the third quarter of fiscal year 2010 was 61.6%, as compared to 63.6% for the third quarter of fiscal year 2009. The lower gross profit margin for the third quarter of fiscal year 2010 was due to increased sales of lower gross profit margin products.

Net sales for the first nine months ended December 31, 2009 totaled $9.65 million, representing a 1% decrease over net sales of $9.71 million for the prior fiscal year's first nine months. The Company recorded net income of $359 thousand, or $.06 per share, for the first nine months of fiscal year 2010, compared to net income of $144 thousand, or $.02 per share, for the first nine months of fiscal year 2009. Gross profit margin for the first nine months of fiscal year 2010 and fiscal year 2009 was 62%.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:  Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

    
    
    
                                    Encision Inc.
                               Condensed Balance Sheets
                                (Amounts in thousands)
    
                                                 December 31,      March 31,
                                                    2009             2009
                                                 (Unaudited)       (Audited)
                                                 -----------       ----------
    ASSETS                                             
    Cash and cash equivalents                         $47              $85 
    Accounts receivable, net                        1,196            1,264 
    Inventories, net                                2,351            2,505 
    Prepaid expenses                                   92               36 
                                                 -----------       ----------
      Total current assets                          3,686            3,890 
                                                 -----------       ----------
    Equipment, net                                  1,095              840 
    Patents, net                                      265              216 
    Other assets                                       27               24 
                                                 -----------       ----------
      Total assets                                 $5,073           $4,970 
                                                 -----------       ----------
    LIABILITIES AND SHAREHOLDERS' EQUITY               
    Accounts payable                                 $373             $745 
    Accrued compensation                              337              406 
    Other accrued liabilities                         388              367 
    Line of credit                                     --              191 
                                                 -----------       ----------
      Total current liabilities                     1,098            1,709 
                                                 -----------       ----------
    Line of credit                                    275               -- 
                                                 -----------       ----------
    Common stock and additional paid-in capital    19,640           19,560 
    Accumulated (deficit)                         (15,940)         (16,299)
                                                 -----------       ----------
      Total shareholders' equity                    3,700            3,261 
                                                 -----------       ----------
      Total liabilities and shareholders' equity   $5,073           $4,970 
                                                 -----------       ----------
    
    
    
                                   Encision Inc.
                         Condensed Statements of Operations
                (Amounts in thousands, except per share information)
    
                                       (Unaudited)            (Unaudited)
                                   Three Months Ended      Nine Months Ended
                                   -------------------    -------------------
                                   December    December   December   December
                                      31,         31,        31,        31,
                                     2009        2008       2009       2008
                                   --------    --------   --------   --------
    Net sales                       $3,260      $3,271    $9,650     $9,711 
    Cost of sales                    1,251       1,192     3,664      3,715
                                   --------    --------   --------   --------
    Gross profit                     2,009       2,079     5,986      5,996 
                                   --------    --------   --------   --------
    Operating expenses:                       
      Sales and marketing            1,146       1,191     3,580      3,887 
      General and administrative       362         355     1,059      1,080 
      Research and development         341         286       947        856 
                                   --------    --------   --------   --------
        Total operating expenses     1,849       1,832     5,586      5,823 
                                   --------    --------   --------   --------
    Operating income                   160         247       400        173 
    Interest and other income 
     (expense), net                    (11)        (14)      (42)       (29)
                                   --------    --------   --------   --------
    Income before provision for 
     income taxes                      149         233       359        144 
    Provision for income taxes          ––          ––        ––         –– 
                                   --------    --------   --------   --------
    Net income                        $149        $233      $359       $144 
                                   ========    ========   ========   ========
    Net income per share-basic       $0.02       $0.04     $0.06      $0.02 
                                   ========    ========   ========   ========
    Net income per share-diluted     $0.02       $0.04     $0.06      $0.02 
                                   ========    ========   ========   ========
    Basic weighted average number        
     of shares                       6,455       6,455     6,455      6,453 
    Diluted weighted average number        
     of shares                       6,461       6,455     6,463      6,453 
    

SOURCE Encision Inc.

RELATED LINKS
http://www.encision.com

'/>"/>

SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zimmer Reports Fourth Quarter and 2009 Financial Results
2. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
3. Lilly Reports Fourth-Quarter and Full-Year 2009 Results
4. P&G Reports Accelerated Sales and Unit Volume Growth
5. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
8. Helix BioPharma Reports On 2009 Annual General Meeting
9. Solos Endoscopy, Inc. Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
10. Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase
11. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):